Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Glaukos stock

GKOS
US3773221029
A14VCK

Price

0
Today +/-
-0
Today %
-0 %
P

Glaukos stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Glaukos stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Glaukos stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Glaukos stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Glaukos's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Glaukos Stock Price History

DateGlaukos Price
9/30/20240 undefined
9/27/20240 undefined
9/26/20240 undefined
9/25/20240 undefined
9/24/20240 undefined
9/23/20240 undefined
9/20/20240 undefined
9/19/20240 undefined
9/18/20240 undefined
9/17/20240 undefined
9/16/20240 undefined
9/13/20240 undefined
9/12/20240 undefined
9/11/20240 undefined
9/10/20240 undefined
9/9/20240 undefined
9/6/20240 undefined
9/5/20240 undefined
9/4/20240 undefined
9/3/20240 undefined

Glaukos Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Glaukos, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Glaukos from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Glaukos’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Glaukos. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Glaukos’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Glaukos’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Glaukos’s growth potential.

Glaukos Revenue, EBIT and net profit per share

DateGlaukos RevenueGlaukos EBITGlaukos Net Income
2029e0 undefined0 undefined0 undefined
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined

Glaukos Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
2204571114159181237225294282314381473592752912991
-900.00125.0057.7860.5639.4713.8430.94-5.0630.67-4.0811.3521.3424.1525.1627.0321.288.66
-90.0075.5681.6985.9686.7986.1983.5459.1177.2175.5376.11------
018345898138156198133227213239000000
-22-14-13-104-2-13-50-118-61-112-123-106-66-4861590
-1,100.00-70.00-28.89-14.083.51-1.26-7.18-21.10-52.44-20.75-39.72-39.17-27.82-13.95-0.6811.4417.43-
-19-12-12-3740-1315-120-49-99-134-117-75-24621050
--36.84-208.33-110.81---215.38-900.00-59.17102.0435.35-12.69-35.90-68.00-358.3369.35-
29.729.729.717.536.534.435.341.144.546.447.448.43000000
------------------
Details

Keystats

ⓘ

Revenue and Growth

The Glaukos Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Glaukos is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
201220132014201520162017201820192020202120222023
                       
1.76.72.391.195.8119140.5174404.4414.1352.7295.43
0.62.95.47.514.316.718.738.436.133.436.139.85
000000000000
0.91.92.34.16.811.213.342.615.82337.841.99
0.40.50.61.43.12.64.17.913.215.617.318.19
3.61210.6104.1120149.5176.6262.9469.5486.1443.9395.46
1.61.922.27.611.819.291.895.5146.1166.8174.54
000000000000
00000020000000
01713.510.26.63.10382.6357.7332.8307.9282.96
000000066.166.166.166.166.13
00.100.10.21.4111516.818.517.721.33
1.61915.512.514.416.330.4555.5536.1563.5558.5544.95
0.010.030.030.120.130.170.210.821.011.0510.94
                       
126.2156.2157.4000000000.05
00.010.010.290.310.330.380.860.980.9511.06
-134.6-147.2-159.4-196.6-192.1-192.2-205.1-189.7-310.1-365.2-464.4-599.07
0000.10.6-0.60.71.310-31.17
000000000000
-3.815.16.295.4117.3138.3174673.3667.5587.2530.1461.9
2.13.33.33.636.26.35.84.47.314.413.44
1.52.16.57.813.920.42451.945.3565860.57
000010010010000000
10.501.9000000000
008.58.900000000
14.15.420.220.31726.730.457.749.763.372.474.01
017.590.800058.4250.1352.7353.6353.31
00000009.610.57.37.37.14
10.70.40.30.20.82.719.427.739.139.244.18
118.29.41.10.20.82.787.4288.3399.1400.1404.63
15.123.629.621.417.227.533.1145.1338462.4472.5478.65
0.010.040.040.120.130.170.210.821.011.0510.94
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Glaukos provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Glaukos's financial health and stability.

Assets

Glaukos's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Glaukos must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Glaukos after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Glaukos's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (k)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201220132014201520162017201820192020202120222023
-22-14-14-3840-1215-120-49-99-134
0144456629293133
0000000-66-12-100
0-11-3-63-3-4-33-13-10
0234318345485129728697
000000005774
000000000001,000
-20-13-7-21226180-2224-33-57
000-15-6-6-10-4-6-47-30-20
600-85-26-12-2643-205-584414
600-69-19-6-1648-198-107534
000000000000
1001-9-900-22287000
019138422182430919
10193107-1421-926239615
000113000-5-498-2-3
000000000000
-34-419-1517143334316-27
-20.99-14.16-7.98-18.076.0319.788.54-5.09-29.93-23.08-63.35-78.01
000000000000

Glaukos stock margins

The Glaukos margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Glaukos. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Glaukos.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Glaukos's sales revenue. A higher gross margin percentage indicates that the Glaukos retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Glaukos's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Glaukos's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Glaukos's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Glaukos. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Glaukos's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Glaukos Margin History

Glaukos Gross marginGlaukos Profit marginGlaukos EBIT marginGlaukos Profit margin
2029e0 %0 %0 %
2028e0 %0 %0 %
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %

Glaukos Stock Sales Revenue, EBIT, Earnings per Share

The Glaukos earnings per share therefore indicates how much revenue Glaukos has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Glaukos earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Glaukos's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Glaukos’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Glaukos's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Glaukos Revenue, EBIT and net profit per share

DateGlaukos Sales per ShareGlaukos EBIT per shareGlaukos Earnings per Share
2029e0 undefined0 undefined0 undefined
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined

Glaukos business model

Glaukos Corp is a medical technology company specializing in developing devices and therapies for treating eye diseases. It was founded in 1998 by employees of the ophthalmology center at the University of California San Francisco. The company focuses on utilizing new technologies and therapies to improve the vision quality of patients. They have developed innovative products for diagnosing and treating various eye conditions, including glaucoma. Their core business involves manufacturing and distributing medical devices for glaucoma treatment, such as the iStent implant. They have also partnered with other institutions to advance research and development in the field of ophthalmology. In 2018, Glaukos Corp acquired the German manufacturer Markt II Medical, expanding their product offerings for a wider range of eye diseases. In summary, Glaukos Corp is an innovative medical technology company that aims to enhance patients' vision quality while minimizing the risks of eye surgery. Glaukos is one of the most popular companies on Eulerpool.com.

Glaukos SWOT Analysis

Strengths

Glaukos Corp possesses several key strengths that contribute to its success in the market:

  • 1. Advanced Technology: Glaukos Corp is known for its innovative and advanced medical devices for the treatment of glaucoma. This technological edge gives them a competitive advantage over other companies in the market.
  • 2. Strong Research and Development: The company invests significantly in research and development, allowing them to continually improve their product offerings and stay ahead of competitors.
  • 3. Established Market Presence: Glaukos Corp has successfully established a strong market presence and brand recognition within the ophthalmic medical device industry.
  • 4. Global Reach: The company operates globally, enabling them to tap into various markets and expand their customer base.

Weaknesses

While Glaukos Corp has several strengths, there are also some weaknesses that need to be addressed for sustainable growth:

  • 1. Dependence on a Single Product Line: The company heavily relies on its core glaucoma treatment products. This can leave them vulnerable to market fluctuations and increases the risk associated with product development.
  • 2. Limited Product Portfolio: Compared to some competitors, Glaukos Corp's product portfolio is relatively narrow. This limits their ability to capture a wider market share or diversify revenue streams.
  • 3. Competitive Market: The ophthalmic medical device industry is highly competitive, with numerous companies vying for market share. Glaukos Corp must continue to innovate and differentiate itself to stay ahead.

Opportunities

Glaukos Corp can leverage the following opportunities to further enhance its position in the market:

  • 1. Growing Ophthalmic Market: The global ophthalmic market is expected to experience solid growth in the coming years. Glaukos Corp can seize this opportunity by expanding its product offerings and entering new geographic markets.
  • 2. Aging Population: With an increasing aging population, there is a higher prevalence of glaucoma and other eye conditions. Glaukos Corp can capitalize on this trend by developing targeted products and services for this demographic.
  • 3. Technological Advancements: Constant advancements in technology offer Glaukos Corp a chance to develop new and improved medical devices, providing better solutions for glaucoma patients and gaining a competitive edge.

Threats

Glaukos Corp faces certain threats that could impact its performance and market position:

  • 1. Regulatory Challenges: The medical device industry is subject to strict regulations and compliance requirements. Any changes or non-compliance with regulatory standards can have adverse effects on Glaukos Corp's operations.
  • 2. Economic Factors: Economic downturns and fluctuations can influence healthcare spending and consumer demand for glaucoma treatment. Glaukos Corp needs to be prepared for potential slowdowns in the market.
  • 3. Competitive Landscape: Intense competition from existing and emerging players in the ophthalmic medical device market poses a constant threat to Glaukos Corp's market share and profitability.

Glaukos Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Glaukos historical P/E ratio, EBIT multiple, and P/S ratio

Glaukos shares outstanding

The number of shares was Glaukos in 2023 — This indicates how many shares 48.433 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Glaukos earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Glaukos's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Glaukos’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Glaukos's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Glaukos.

Glaukos latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240 0  (1.01 %)2024 Q2
3/31/20240 0  (-19.54 %)2024 Q1
12/31/20230 0  (-12.32 %)2023 Q4
9/30/20230 0  (10.67 %)2023 Q3
6/30/20230 0  (2.76 %)2023 Q2
3/31/20230 0  (-0.56 %)2023 Q1
12/31/20220 0  (4.74 %)2022 Q4
9/30/20220 0  (15.49 %)2022 Q3
6/30/20220 0  (-85.89 %)2022 Q2
3/31/20220 0  (26.27 %)2022 Q1
1
2
3
4

Eulerpool ESG Scorecard© for the Glaukos stock

Eulerpool World ESG Rating (EESG©)

66/ 100

🌱 Environment

40

👫 Social

99

🏛️ Governance

58

Environment

Scope 1 - Direct Emissions
569.4
Scope 2 - Indirect emissions from purchased energy
1,360.2
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
1,929.6
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees38
Percentage of women in management—
Percentage of Asian employees23
Share of Asian management—
Percentage of Hispanic/Latino employees11
Hispano/Latino Management share—
Percentage of Black employees2
Black Management Share—
Percentage of white employees57
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Glaukos shareholders

%
Name
Stocks
Change
Date
9.51341 % The Vanguard Group, Inc.5,227,617-3,27912/31/2023
8.84575 % Fidelity Management & Research Company LLC4,860,7411,694,93112/31/2023
4.90954 % Brown Capital Management, LLC2,697,79489,42012/31/2023
3.30648 % State Street Global Advisors (US)1,816,91151,10412/31/2023
2.99378 % Fred Alger Management, LLC1,645,081-135,60912/31/2023
2.94183 % Janus Henderson Investors1,616,5341,35712/31/2023
2.68010 % Burns (Thomas William)1,472,715-18,3274/5/2024
2.45469 % Invesco Advisers, Inc.1,348,850149,40712/31/2023
2.43949 % Wellington Management Company, LLP1,340,500-715,92112/31/2023
2.22551 % Artisan Partners Limited Partnership1,222,916-121,66512/31/2023
1
2
3
4
5
...
10

Glaukos Executives and Management Board

Mr. Joseph Gilliam47
Glaukos President, Chief Operating Officer
Compensation 6.97 M
Mr. Thomas Burns62
Glaukos Chairman of the Board, Chief Executive Officer (since 2002)
Compensation 6.27 M
Dr. Tomas Navratil46
Glaukos Chief Development Officer
Compensation 2.42 M
Mr. Alex Thurman53
Glaukos Chief Financial Officer, Senior Vice President
Compensation 2.13 M
Mr. Mark Foley57
Glaukos Lead Independent Director
Compensation 307,895
1
2
3

Most common questions regarding Glaukos

What values and corporate philosophy does Glaukos represent?

Glaukos Corp represents a set of core values and a corporate philosophy that drives its operations. The company is committed to advancing the field of ophthalmic medical technology and improving the lives of patients with glaucoma. Glaukos Corp follows a patient-centric approach, focusing on developing innovative and minimally invasive treatment options for the eye disease. With a strong dedication to research and development, Glaukos Corp aims to provide effective and sustainable therapies. The company's vision is to become the global leader in micro-scale devices for glaucoma, offering groundbreaking solutions to enhance patients' quality of life. Through its unwavering commitment and innovative spirit, Glaukos Corp continues to revolutionize the way glaucoma is treated.

In which countries and regions is Glaukos primarily present?

Glaukos Corp is primarily present in the United States with headquarters located in San Clemente, California.

What significant milestones has the company Glaukos achieved?

Since its establishment, Glaukos Corp has achieved several noteworthy milestones. The company's pioneering technologies have revolutionized the field of ophthalmic surgery, offering innovative solutions for glaucoma treatment. Glaukos Corp's breakthrough product, iStent®, became the first-ever micro-invasive glaucoma surgery device approved by the FDA. This milestone marked a major advancement in improving the lives of glaucoma patients worldwide. Additionally, Glaukos Corp has expanded its product portfolio, introducing iStent inject® and iStent inject®W, further solidifying the company's commitment to providing effective and minimally invasive solutions for reducing intraocular pressure. With these accomplishments, Glaukos Corp continues to lead the way in the advancement of glaucoma treatment.

What is the history and background of the company Glaukos?

Glaukos Corp is a renowned medical technology company specializing in developing and commercializing innovative products for glaucoma treatment. Founded in 1998, Glaukos Corp has a rich history of revolutionizing the field of ophthalmology. Since its inception, the company has introduced groundbreaking glaucoma therapies, including the iStent®, the world's first MIGS (Micro-Invasive Glaucoma Surgery) device. Glaukos Corp is committed to providing sustainable solutions for patients suffering from glaucoma, a leading cause of blindness. With its cutting-edge technologies, the company has transformed glaucoma management, offering safer and effective treatment options. Glaukos Corp continues to shape the future of glaucoma care through its dedication to innovation and improving patients' lives.

Who are the main competitors of Glaukos in the market?

The main competitors of Glaukos Corp in the market are Alcon Inc., Bausch Health Companies Inc., and Johnson & Johnson Vision.

In which industries is Glaukos primarily active?

Glaukos Corp is primarily active in the medical devices industry.

What is the business model of Glaukos?

The business model of Glaukos Corp revolves around developing and commercializing innovative ophthalmic medical devices for the treatment of glaucoma. The company's flagship product, iStent, is a tiny implant inserted into the eye to restore the natural outflow of fluid, thereby reducing intraocular pressure and controlling the progression of glaucoma. Glaukos Corp also offers complementary products and technologies, such as the iStent inject, iStent SA, and iDose. By focusing on the development of minimally invasive therapies, Glaukos Corp aims to improve patient outcomes and quality of life while addressing the growing global demand for effective glaucoma treatments.

What is the P/E ratio of Glaukos 2024?

The P/E ratio cannot be calculated for Glaukos at the moment.

What is the P/S ratio of Glaukos 2024?

The P/S cannot be calculated for Glaukos currently.

What is the AlleAktien quality score of Glaukos?

The AlleAktien quality score for Glaukos is 5/10.

What is the revenue of Glaukos 2024?

The revenue cannot currently be calculated for Glaukos.

How high is the profit of Glaukos 2024?

The profit cannot currently be calculated for Glaukos.

What is the business model of Glaukos

Glaukos Corp is a publicly traded company (NYSE: GKOS) specializing in the development, manufacturing, and marketing of ophthalmological devices and products. The company was founded in 1998 and is headquartered in San Clemente, California. Glaukos Corp has several divisions, including the iStent system, Hydrus Microstent, iDose system, as well as individual and accessory products. The iStent system is the first FDA-approved microimplant for use in patients with open-angle glaucoma (OWG). The iStent injector system is an injector that allows for easy placement of the iStent into the Schlemm's canal. The Hydrus Microstent system is a microscopic stent that is inserted into the Schlemm's canal to improve blood flow in the eyes. The iDose system is a drug-delivery implant used for continuous and precise administration of ophthalmic medications. Glaukos also offers individual products such as the TRAB 360 implant needle and the iStent bayonet insertion device. Accessory products such as gonioscopy lenses, lid speculum, microstents, and trabeculectomy kits complement the offering. Glaukos Corp's business model is based on addressing market niches that have not been sufficiently treated by conventional methods. With its products, Glaukos aims to improve the safety and effectiveness of eye surgeries while meeting the needs of physicians and patients. To support its expansion, Glaukos has also formed strategic partnerships with other companies in the industry. In 2018, the company announced a collaboration with Santen Pharmaceutical Co., Ltd., a leading company in the ophthalmic industry. This collaboration includes the development of drug products and devices. Another important aspect of Glaukos' business model is investment in research and development. The company is strongly committed to innovation and has made significant investments in developing new products in recent years. In summary, Glaukos Corp offers a wide range of ophthalmological products and systems. The company focuses on closing gaps in the treatment of eye diseases by developing and distributing innovative solutions worldwide. Through its innovative technology and strong commitment to research and development, the company has established itself as a market leader in its field.

What is the Glaukos dividend?

Glaukos pays a dividend of 0 USD distributed over payouts per year.

How often does Glaukos pay dividends?

The dividend cannot currently be calculated for Glaukos or the company does not pay out a dividend.

What is the Glaukos ISIN?

The ISIN of Glaukos is US3773221029.

What is the Glaukos WKN?

The WKN of Glaukos is A14VCK.

What is the Glaukos ticker?

The ticker of Glaukos is GKOS.

How much dividend does Glaukos pay?

Over the past 12 months, Glaukos paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Glaukos is expected to pay a dividend of 0 USD.

What is the dividend yield of Glaukos?

The current dividend yield of Glaukos is .

When does Glaukos pay dividends?

Glaukos pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Glaukos?

Glaukos paid dividends every year for the past 0 years.

What is the dividend of Glaukos?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Glaukos located?

Glaukos is assigned to the 'Health' sector.

Wann musste ich die Aktien von Glaukos kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Glaukos from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Glaukos pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Glaukos in the year 2023?

In the year 2023, Glaukos distributed 0 USD as dividends.

In which currency does Glaukos pay out the dividend?

The dividends of Glaukos are distributed in USD.

All fundamentals about Glaukos

Our stock analysis for Glaukos Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Glaukos Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.